Double maintains 3 strategies that include RXRX - Recursion Pharmaceuticals, Inc.
Current Value
$5.241 Year Return
Current Value
$5.241 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FE | -<0.01% | $22.95B | +3.43% | 4.32% |
| WEC | -0.08% | $33.11B | +33.56% | 3.32% |
| GFI | -0.11% | $21.56B | +57.55% | 2.31% |
| JNJ | 0.18% | $374.29B | +6.77% | 3.23% |
| VSTA | -0.21% | $344.07M | +39.29% | 0.00% |
| SPTN | -0.24% | $898.36M | +47.04% | 3.30% |
| PEP | -0.30% | $187.12B | -16.06% | 4.02% |
| CWT | -0.31% | $2.75B | -3.24% | 2.50% |
| HSY | 0.31% | $35.88B | -3.63% | 3.10% |
| PGR | 0.33% | $151.13B | +22.60% | 1.89% |
| GO | -0.38% | $1.28B | -39.16% | 0.00% |
| PRA | -0.39% | $1.17B | +89.68% | 0.00% |
| PPL | 0.40% | $24.79B | +21.83% | 3.15% |
| PULM | -0.41% | $25.57M | +219.63% | 0.00% |
| HTO | 0.47% | $1.82B | -0.39% | 3.10% |
| GIS | 0.52% | $29.20B | -14.66% | 4.47% |
| DOGZ | -0.57% | $121.58M | -48.38% | 0.00% |
| FIZZ | 0.67% | $4.20B | -13.13% | 0.00% |
| DG | 0.74% | $25.41B | -7.95% | 2.05% |
| FDP | -0.79% | $1.59B | +52.62% | 3.31% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRSP | 72.37% | $4.46B | -4.14% | 0.00% |
| BEAM | 63.30% | $2.00B | -15.33% | 0.00% |
| ABCL | 60.55% | $1.12B | +38.38% | 0.00% |
| NTLA | 57.54% | $1.11B | -53.25% | 0.00% |
| SDGR | 56.34% | $1.54B | +4.28% | 0.00% |
| NNOX | 56.31% | $339.85M | -24.50% | 0.00% |
| TWST | 56.18% | $2.26B | -21.50% | 0.00% |
| ROKU | 56.12% | $12.67B | +38.71% | 0.00% |
| IMNM | 55.52% | $750.92M | -28.80% | 0.00% |
| CERS | 55.37% | $298.21M | -9.30% | 0.00% |
| FATE | 54.71% | $128.39M | -64.56% | 0.00% |
| EYPT | 53.31% | $664.72M | +12.07% | 0.00% |
| SOFI | 52.90% | $20.03B | +177.91% | 0.00% |
| CRBU | 52.83% | $127.42M | -14.38% | 0.00% |
| BNT | 52.49% | $12.59B | +45.18% | 0.00% |
| BN | 52.48% | $103.22B | +45.48% | 0.54% |
| SLAB | 52.09% | $4.97B | +37.05% | 0.00% |
| LSCC | 51.96% | $7.19B | -16.13% | 0.00% |
| AMBA | 51.67% | $2.81B | +16.04% | 0.00% |
| DNLI | 51.52% | $2.16B | -30.05% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -22.47% | $24.23B | +35.36% | 1.09% |
| ED | -18.15% | $36.00B | +12.64% | 3.34% |
| CME | -14.98% | $99.39B | +40.68% | 3.86% |
| MO | -14.77% | $99.67B | +28.77% | 6.90% |
| DUK | -12.73% | $90.99B | +17.25% | 3.56% |
| AWK | -11.87% | $27.36B | +9.65% | 2.21% |
| SO | -11.53% | $100.18B | +17.28% | 3.18% |
| KR | -10.26% | $46.43B | +38.38% | 1.85% |
| PM | -7.83% | $273.81B | +73.45% | 3.06% |
| EXC | -7.27% | $43.33B | +23.58% | 3.62% |
| AEP | -7.18% | $55.16B | +17.93% | 3.54% |
| K | -6.44% | $27.76B | +41.17% | 2.85% |
| KMB | -6.38% | $43.92B | -3.75% | 3.75% |
| T | -6.32% | $203.71B | +51.55% | 3.92% |
| VSA | -5.84% | $8.67M | -19.04% | 0.00% |
| LITB | -5.84% | $21.24M | -78.57% | 0.00% |
| MCK | -5.79% | $88.11B | +20.93% | 0.40% |
| AMT | -4.43% | $104.32B | +14.40% | 3.00% |
| CMS | -4.26% | $20.85B | +18.38% | 3.02% |
| CL | -3.63% | $74.88B | -3.64% | 2.19% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ARKG | 81.16% | $1.02B | 0.75% |
| GNOM | 69.78% | $44.57M | 0.5% |
| ARKK | 69.77% | $6.85B | 0.75% |
| XBI | 65.06% | $4.82B | 0.35% |
| KOMP | 63.63% | $2.29B | 0.2% |
| IWO | 62.04% | $11.60B | 0.24% |
| IWC | 61.87% | $818.14M | 0.6% |
| ROBT | 61.84% | $498.76M | 0.65% |
| BUZZ | 61.54% | $65.84M | 0.76% |
| IBUY | 61.32% | $151.71M | 0.65% |
| VBK | 61.04% | $19.01B | 0.07% |
| ARKF | 60.70% | $1.20B | 0.75% |
| QQQJ | 60.37% | $621.52M | 0.15% |
| CWB | 60.26% | $3.88B | 0.4% |
| PTH | 60.22% | $100.85M | 0.6% |
| DRIV | 60.00% | $303.50M | 0.68% |
| ARKQ | 59.99% | $1.10B | 0.75% |
| PBW | 59.89% | $271.53M | 0.65% |
| XT | 59.86% | $3.40B | 0.46% |
| ISCG | 59.51% | $681.20M | 0.06% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| MMIT | -0.07% | $1.03B | 0.3% |
| SMB | -0.12% | $274.97M | 0.07% |
| ITM | 0.17% | $1.87B | 0.18% |
| FMB | 0.28% | $1.90B | 0.65% |
| TBLL | 0.36% | $2.13B | 0.08% |
| SCHP | 0.52% | $12.99B | 0.03% |
| DFIP | 0.54% | $925.62M | 0.11% |
| TIPX | 0.60% | $1.74B | 0.15% |
| GTIP | -0.76% | $164.52M | 0.12% |
| OWNS | -0.80% | $129.31M | 0.3% |
| USTB | -0.91% | $1.29B | 0.35% |
| GVI | -0.91% | $3.42B | 0.2% |
| JPLD | -0.94% | $1.77B | 0.24% |
| TAXF | 1.03% | $489.34M | 0.29% |
| SHYD | 1.12% | $332.63M | 0.35% |
| JSI | 1.13% | $874.13M | 0.49% |
| MMIN | -1.20% | $336.10M | 0.3% |
| BIL | 1.45% | $42.24B | 0.1356% |
| HTAB | 1.47% | $411.35M | 0.39% |
| NYF | 1.52% | $892.18M | 0.25% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -53.78% | $296.22M | 1.43% |
| VIXY | -45.71% | $164.54M | 0.85% |
| TAIL | -45.26% | $99.63M | 0.59% |
| IVOL | -24.24% | $347.03M | 1.02% |
| SPTS | -15.36% | $5.80B | 0.03% |
| LDUR | -14.69% | $929.65M | 0.5% |
| FTSD | -14.57% | $231.81M | 0.25% |
| SHYM | -13.54% | $357.13M | 0.35% |
| UTWO | -13.43% | $379.52M | 0.15% |
| SCHO | -13.19% | $11.03B | 0.03% |
| XONE | -12.83% | $625.28M | 0.03% |
| VGSH | -12.51% | $22.80B | 0.03% |
| IBTG | -12.08% | $1.92B | 0.07% |
| STPZ | -11.60% | $450.47M | 0.2% |
| IBTI | -11.54% | $1.06B | 0.07% |
| IBTH | -11.17% | $1.62B | 0.07% |
| IBTJ | -10.34% | $688.19M | 0.07% |
| BSMW | -10.30% | $107.45M | 0.18% |
| IEI | -10.08% | $15.48B | 0.15% |
| FXY | -10.01% | $816.38M | 0.4% |
Yahoo
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.27, denoting a +1.15% move from the preceding trading day.
Yahoo
Investing.com -- Morgan Stanley initiated coverage on three AI-integrated biotechnology firms, Absci, Schrodinger (NASDAQ:SDGR), and Recursion Pharmaceuticals, flagging divergent business models and upcoming catalysts in a sector under pressure.
Yahoo
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks to buy according to hedge funds. Earlier on June 6, a significant advancement in drug discovery was announced with the open-source release of Boltz-2, which is a biomolecular foundation model developed through a collaboration between researchers at the Massachusetts Institute of Technology (or MIT) […]
Yahoo
Recursion’s slow and steady start could lead to a bright future in biotech.
Yahoo
Recursion Pharmaceuticals (RXRX) reached $5.03 at the closing of the latest trading day, reflecting a -6.85% change compared to its last close.
Yahoo
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of 10 AI stocks that will skyrocket. Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an Equal Weight rating on the stock. The revision comes in response to the company’s recent strategic updates, including a restructured pipeline, workforce reduction, and revised […]
